Dr. Reddy’s introduces azole antifungal tablets in U.S.
The Hindu
HYDERABAD
Drugmaker Dr. Reddy’s Laboratories has introduced Posaconazole Delayed-Release Tablets, 100 mg in the U.S.
An azole antifungal, the product is a therapeutic generic equivalent to Noxafil (posaconazole) Delayed-Release Tablets, 100 mg and has been introduced following U.S. Food and Drug Administration’s approval, the company said. It is indicated for prophylaxis of certain fungal infections in severely immunocompromised patients.
The Noxafil brand and generic had U.S. sales of approximately $140.8 million MAT for the most recent 12 months ended February 2022, Dr. Reddy’s said citing IQVIA numbers.
xAI’s Grok may soon come to an iOS app as the company announced its Series C funding round of $6 billion.
Biocon and Zentiva receive EU approval for Liraglutide, a complex formulation for diabetes and weight management.
Equity markets fluctuate as Sensex and Nifty rise initially, then fall; global markets and oil prices also discussed.
Microsoft has been working on adding internal and third-party AI models to power Microsoft 365 Copilot.
China's dominance in critical minerals poses supply chain vulnerabilities for India, US, and EU nations, requiring strategic diversification efforts.
India's controversial popcorn tax system sparks outrage and criticism, with opposition questioning the complex GST rates.
ICAI President investigates auditing lapses at Byju's, disciplinary committee probing, details undisclosed, part of ongoing investigations.
Sensex and Nifty rebound sharply after steep decline, driven by value buying, bluechip stocks, and global market rally.
AS-IT-IS Nutrition aims for ₹300 crore GMV in 2025 with ATOM range, endorsed by Ravindra Jadeja.
Adani Group acquires Air Works, India's largest MRO company, expanding its aviation services with a ₹400 crore deal.
Sterling and Wilson Renewable Energy Ltd. secures ₹1,200 crore order for 500 MW Solar PV project in Gujarat.